celecoxib oral

At 12 weeks, it significantly enhanced tissue maturation and collagen arrangement in the defect area and mitigated cartilage degeneration. This strategy guides meniscus healing with a dual function by modulating the inflammatory environment while providing biomimetic structural support.

In response to lipopolysaccharide stimulation, both extracts had anti-inflammatory effects like those of the control medication celecoxib, which decreased 5-LOX and TNF-α expression by 0.3554-fold and 0.2263-fold, respectively. Molecular docking highlighted that dihydrosterculic acid showed the tightest fit within 5-LOX center revealing binding energy (∆G = -35.09 kcal/mol). Consequently, this study highlighted the relevance of the flowers of both Ceiba species in treating inflammatory disorders that in turn confirmed the traditional medicinal uses of these plants.

Its effects were comparable to COX-2 gene silencing, with a favorable preclinical safety profile supporting long-term clinical use. These findings elucidate the neuroprotective mechanism of celecoxib, propose COX-2/PGE2 as a therapeutic target for CIPN, and lay a foundation for relevant combination therapy research, highlighting celecoxib's potential in CIPN management.

P=N/A, N=40, Recruiting, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027

The combined therapy also increases the overall efficacy rate, reduces the effecting time, without increasing systemic adverse events. The combined regimen represents an effective and safe treatment option to offer benefits for clinical application.

P4, N=41, Completed, Stony Brook University | Active, not recruiting --> Completed | Trial primary completion date: Feb 2026 --> Aug 2025

P4, N=42, Not yet recruiting, Stony Brook University | Trial completion date: Jan 2031 --> Jan 2032 | Trial primary completion date: Jun 2030 --> Jun 2031

P3, N=53, Completed, Ferring Ventures Limited | Active, not recruiting --> Completed

These findingssuggest that LDRT combined with ICB is safe and may contribute to immunomodulatory activity in immune-excluded tumors. CD8⁺ TIL dynamics, DNA repair responsiveness, and TME composition may predict response and merit further validation in controlled larger studies.

One group received an intra-articular saline injection as the normal control (NC), while the remaining five groups were injected with monosodium iodoacetate (MIA) and consisted of an MIA control group (MC), a positive control group treated with celecoxib (PC, 3 mg/kg), and three groups treated with CP (31.25, 62.5, or 125 mg/kg)...Furthermore, CP decreased the activation of nuclear factor kappa B (NF-κB) signaling. These findings suggest that CP may be a promising functional agent for osteoarthritis, demonstrating beneficial effects on pain-related outcomes and cartilage integrity, potentially mediated by its anti-inflammatory activity.

ADME and ProTox-3.0 predictions suggested favorable drug-likeness and low acute oral toxicity, while molecular docking indicated that the lead compound 7b established stable interactions with voltage-gated calcium channels and cyclooxygenase-2, exhibiting binding modes comparable to sodium valproate and celecoxib, respectively. Remarkable anticonvulsant efficacy was observed in both the pentylenetetrazole (PTZ) induced seizure model and pilocarpine-induced seizure model, where 7b afforded 90% seizure protection with complete prevention of mortality, delayed seizure onset by 156.43%, reduced seizure severity by 70.53%, and achieved 100% survival, surpassing sodium valproate. Mechanistically, 7b markedly attenuated hippocampal neuroinflammation and excitotoxicity, reducing TNF-α, IL-6, and glutamate levels while suppressing glial activation markers glial fibrillary acidic protein and ionized calcium-binding adapter molecule 1, confirming pronounced neuroprotective and anti-neuroinflammatory effects.